ADME-Toxicology Testing Market Analysis, Share and Future Scope

ADME stands for absorption, distribution, metabolism and elimination of the drug and chemicals define their nature in a human body. These four methods define the impact of a specific drug or chemical to the human tissues. Toxicology testing is an important phenomenon before introducing new medicine to the market. ADME toxicology facilitated pharmaceutical manufacturing company to minimize their drug discovery time, testing complications, and to reduce the cost of drug development.

Browse report sample at: http://bit.ly/2Nu7SYQ

ADME-toxicology testing has witnessed significant growth in the drug development in recent years. Most often the development of new drug is a very critical for the drug developers, attributed mainly to the high cost proposal for pharmaceutical and large attrition rate at various stages of drug development. The conventional drug development uses vivo model of toxicity testing.

Based on the different product type, global ADME-toxicology testing market can be bifurcated as instruments, software solutions, assays systems, reagents and others. Based on the technology used in the ADME-toxicology testing the market can be bifurcated as in-vivo (implemented inside a living organism), and in-vitro (test performed in a laboratory). Further In-vitro technology is bifurcated as biochemical testing and cell testing (including liver, intestinal, kidney). In-vitro technology is expected to witness the highest growth during the forecast period attributed mainly to the growing concern over animal rights for using animals for clinical trials. In-vivo is still the largest used toxicity testing technology owing to its cost and time benefits over other toxicity testing technique. With benefits such as increase throughput screening, the ADME toxicology prediction technology is expected to increase in coming years.

Browse report at: http://bit.ly/2H4CW0g

Asia Pacific is expected to be the fasted growing market of ADME-Toxicology Testing during the forecast period. The growth is mainly anticipated from the supporting government initiatives and increasing number of merger and accusation (M&A) in pharmaceutical companies and research laboratories.

Some of the major players operating in the Global ADME-Toxicology Testing Market include, Accelrys, Inc., Agilent Technologies, Inc., Caliper Life Sciences, Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Cellartis AB, Cyprotex PLC., Life Technologies Corporation, Optivia Biotechnology, Inc., Thermo Fisher Scientific, Inc., Molecular Discovery Ltd., Cyprotex PLC, MultiCASE, Inc., Promega Corporation, Xceleron, Inc., ACEA Biosciences, Inc., Albany Molecular Research, Inc., Beckman Coulter, Inc., CeeTox, Inc., Molecular Discovery Ltd.

Source: P&S Intelligence

Increasing Demand for Silicon-Based Scar Treatment Products is a Trend in the Market

Silicon-based products, such as gels and gel sheets, are effective for reducing scars and are recommended by cosmetic surgeons and doctors, globally. These products provide effective results and help in fading away of the scars completely. They are very effective and are used widely for treating all type of scars, including stretch marks, hypertrophic, keloid, acne and post-surgical scars. These products also help in reduction of the size and darkness of the scars. Some of the silicone-based scar removal products available in market include Avosil Scar Care Ointment, Kelo-Cote, Xeragel, Kelo-cote spray, Avogel, Cimeosil, Oleeva, and ScarAway. Since these silicon-based products are more efficient in treating scars and offer advantages over conventional scar treatment products, this is expected to further accelerate the demand of silicon-based scar treatment products and drive the growth of the scar treatment market.

Download report sample at: http://bit.ly/2GSLOGh

North America stands as the largest scar treatment market

Geographically, North America was the largest market scar treatment market in 2016 and is expected to contribute 40.5 % by 2023. This dominant position of the region is primarily attributable to high disposable income, which further increases spending on personal care products. Moreover, the increasing appearance consciousness among the population in the region has also led to a rise in the adoption of technologically advanced scar treatment products.

According to the AAD, approximately 85% of the population in the U.S. suffers from acne, every year. The growing awareness about various technologies, which can enhance physical appearance of an individual is driving the demand for advanced scar treatment products in the U.S. The Asian scar treatment market is expected to grow at a faster rate as compared to the other regions, owing to growing focus on personal well-being, increasing disposable income and rising prevalence of skin related problems in the region.

Browse report at: http://bit.ly/2GX6QmX

GLOBAL SCAR TREATMENT MARKET SEGMENTATION
By Type of Treatment
• Topical
• Surface
• Laser
• Injectable
• Invasive surgical
By Type of Scar
• Post-surgical scar
• Acne scar
• Keloid scar and hypertrophic scar
• Contracture scar
• Stretch marks scar
By End User
• Hospital
• Private Clinic
• Pharmacies and drug store
• E-commerce

Source: P&S Intelligence

Antibody Drug Conjugates Therapeutics Market Trends, Share and Future Scope

The global antibody drug conjugates therapeutics market is expected to witness significant growth due to current unmet medical need of some chronic diseases such as cancer and immunological diseases, increasing prevalence of such diseases, advancement in technologies and high demand for safe and effective medication. The regulatory bodies are supporting the ADCs market by providing designations and funding for speeding up the drug development process. In April 2015, ImmunoGen, Inc. drug candidate Mirvetuximab soravtansine got orphan drug designation by European Medicine Agency for the treatment of ovarian cancer.

Download report sample at: http://bit.ly/2zop4rV

ADCs are prepared by linking biologically active cytotoxic drugs to monoclonal antibodies. An ADC comprises of a monoclonal antibody, cytotoxic drug and a linker. ADCs have specific targeting ability of monoclonal antibody, and hence these are capable of distinguishing healthy and diseased cells. Moreover, the cancer-killing ability of cytotoxic drugs makes ADCs more effective against the tumor cells. These characteristics increase the specificity and maximize the efficacy of ADCs. The antibody component of ADCs recognizes the target antigen and binds with it. After binding with the antigen, the cytotoxic component is released inside the tumor cell, causing its death or degeneration. The significant potential of ADCs in cancer treatment has attracted many researchers and healthcare providers to develop new antibody therapeutics using ADC technology.

A large number of pharmaceutical companies are focusing towards research and development of ADCs. However, certain factors such as unknown etiology, complex pathophysiology and high treatment cost of cancer are expected to hamper the growth of the global market during the forecast period.

Browse report at: http://bit.ly/2mKy7fi

Some of the key players operating in the global market are ImmunoGen, Inc., Takeda Pharmaceutical Company Limited, Seattle Genetics, Inc., F. Hoffmann-La Roche AG, BioAtla LLC, Philogen S.p.A., Viventia Biotechnologies, Inc., Sutro Biopharma, Inc., Sorrento Therapeutics, Inc., and Immunobiochem Corporation.

Source: P&S Intelligence